Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05993949 · ClinicalTrials.gov registry record · Phase 1
Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
A Phase 1 study of Lymphoblastic Leukemia, sponsored by Stanford University.
- Active
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT05993949: Active Phase 1 study of Lymphoblastic Leukemia, sponsored by Stanford University.
NCT05993949 is a Phase 1 study of Lymphoblastic Leukemia that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 8 participants, below the 41-participant average among 6 other Lymphoblastic Leukemia trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05993949, a Phase 1 study of Lymphoblastic Leukemia, is active but no longer recruiting, sponsored by Stanford University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the feasibility of oral dasatinib pulses (3 consecutive days per week) during the first month following infusion of brexucabtagene autoleucel (Tecartus) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
Primary Outcome
Feasibility of administering oral dasatinib pulses (3 consecutive doses per week) during the first month following Tecartus infusion. Feasibility will be defined as the ability of 8 out of 20 subjects to miss no more than one cycle (defined as one week of at least three consecutive days of dasatinib) within the first month following Tecartus infusion.
Conditions Studied
Interventions
- DRUG Dasatinib
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-10-02 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What the registry record for NCT05993949 still lists
NCT05993949 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 41-participant average among 6 other Lymphoblastic Leukemia trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Dasatinib is the first listed.
NCT05993949 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05993949 about?
NCT05993949 is a clinical study titled "Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia". To assess the feasibility of oral dasatinib pulses (3 consecutive days per week) during the first month following infusion of brexucabtagene autoleucel (Tecartus) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
What is the current status of trial NCT05993949?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2023-10-02. Estimated completion is 2027-06.
What conditions does trial NCT05993949 study?
This clinical trial studies the following conditions: Lymphoblastic Leukemia.
What interventions are being tested in trial NCT05993949?
The interventions under investigation include: Dasatinib (DRUG).
Who is sponsoring clinical trial NCT05993949?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05993949 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
RECRUITING · Phase 1
-
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
RECRUITING · Phase 1
-
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
ACTIVE NOT RECRUITING · Phase 1
-
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
RECRUITING · Phase 2
-
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
RECRUITING · Phase 2
-
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI